# A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

> **NCT06003231** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Seagen, a wholly owned subsidiary of Pfizer** · enrollment: 120 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung
- Ovarian Neoplasms
- Endometrial Neoplasms
- Head and Neck Neoplasms

## Interventions

- **DRUG:** disitamab vedotin

## Key facts

- **NCT ID:** NCT06003231
- **Lead sponsor:** Seagen, a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-11-14
- **Primary completion:** 2026-05-31
- **Final completion:** 2028-05-31
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06003231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06003231, "A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06003231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*